115 related articles for article (PubMed ID: 16706321)
1. ACE inhibitor use and mortality reduction: do controlled trial results equal clinical practice?
Schade CP; Hannah KL; Rezek G; Brehm JG
W V Med J; 2006; 102(1):304-6. PubMed ID: 16706321
[TBL] [Abstract][Full Text] [Related]
2. Patterns of physician use of angiotensin converting enzyme inhibitors in the inpatient treatment of congestive heart failure.
Ghali JK; Giles T; Gonzales M; Horswell R; Kumar S; Lejuene A; Livaudais GF; Sarkar IC
J La State Med Soc; 1997 Dec; 149(12):474-84. PubMed ID: 9425858
[TBL] [Abstract][Full Text] [Related]
3. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge.
Butler J; Arbogast PG; Daugherty J; Jain MK; Ray WA; Griffin MR
J Am Coll Cardiol; 2004 Jun; 43(11):2036-43. PubMed ID: 15172409
[TBL] [Abstract][Full Text] [Related]
4. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
Masoudi FA; Rathore SS; Wang Y; Havranek EP; Curtis JP; Foody JM; Krumholz HM
Circulation; 2004 Aug; 110(6):724-31. PubMed ID: 15289383
[TBL] [Abstract][Full Text] [Related]
5. A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications.
Ahmed A; Centor RM; Weaver MT; Perry GJ
Am Heart J; 2005 Apr; 149(4):737-43. PubMed ID: 15990761
[TBL] [Abstract][Full Text] [Related]
6. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
7. Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors.
Setoguchi S; Levin R; Winkelmayer WC
Int J Cardiol; 2008 Apr; 125(2):172-7. PubMed ID: 17997175
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic heart failure in a managed care setting. Baseline results from the Achieving Cardiac Excellence Project.
Schmedtje JF; Evans GW; Byerly W; King M; Goonan K; Blastock-Glenn C; Croft JB; Goff DC
N C Med J; 2003; 64(1):4-10. PubMed ID: 12774552
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
11. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
Gotsman I; Rubonivich S; Azaz-Livshits T
Isr Med Assoc J; 2008 Mar; 10(3):214-8. PubMed ID: 18494235
[TBL] [Abstract][Full Text] [Related]
12. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
13. Impact of opinion leader-endorsed evidence summaries on the quality of prescribing for patients with cardiovascular disease: a randomized controlled trial.
Majumdar SR; Tsuyuki RT; McAlister FA
Am Heart J; 2007 Jan; 153(1):22.e1-8. PubMed ID: 17174632
[TBL] [Abstract][Full Text] [Related]
14. Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
Hess G; Preblick R; Hill J; Plauschinat CA; Yaskin J
Congest Heart Fail; 2009; 15(4):170-5. PubMed ID: 19627290
[TBL] [Abstract][Full Text] [Related]
15. Heart failure mortality among older Medicare beneficiaries: association with left ventricular function evaluation and angiotensin-converting enzyme inhibitor use.
Ahmed A; Maisiak R; Allman RM; DeLong JF; Farmer R
South Med J; 2003 Feb; 96(2):124-9. PubMed ID: 12630634
[TBL] [Abstract][Full Text] [Related]
16. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors?
McMurray JJ
Eur Heart J; 1998 Oct; 19 Suppl L():L15-21. PubMed ID: 9821004
[TBL] [Abstract][Full Text] [Related]
17. Underutilization of angiotensin converting enzyme inhibitors among heart failure patients.
Lean QY; Shamsuddin N; Wan Ahmad WA
Med J Malaysia; 2008 Aug; 63(3):216-21. PubMed ID: 19248693
[TBL] [Abstract][Full Text] [Related]
18. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
Dulin BR; Krum H
Curr Opin Cardiol; 2006 Jul; 21(4):393-9. PubMed ID: 16755210
[TBL] [Abstract][Full Text] [Related]
19. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
Tokmakova M; Solomon SD
Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
